Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study)
- Author:
Grace S. AHN
1
;
Kihwan HWANG
;
Tae Min KIM
;
Chul Kee PARK
;
Jong Hee CHANG
;
Tae-Young JUNG
;
Jin Hee KIM
;
Do-Hyun NAM
;
Se-Hyuk KIM
;
Heon YOO
;
Yong-Kil HONG
;
Eun-Young KIM
;
Dong-Eun LEE
;
Jungnam JOO
;
Yu Jung KIM
;
Gheeyoung CHOE
;
Byung Se CHOI
;
Seok-Gu KANG
;
Jeong Hoon KIM
;
Chae-Yong KIM
Author Information
- Publication Type:Original Article
- From:Cancer Research and Treatment 2022;54(2):396-405
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:The KNOG-1101 study showed improved 2-year PFS with temozolomide during and after radiotherapy compared to radiotherapy alone for patients with anaplastic gliomas. This trial investigates the effect of concurrent and adjuvant temozolomide on health-related quality of life (HRQoL).
Materials and Methods:In this randomized, open-label, phase II trial, 90 patients with World Health Organization grade III glioma were enrolled across multiple centers in South Korea between March 2012 to February 2015 and followed up through 2017. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC QLQ-C30) and 20-item EORTC QLQ-Brain Neoplasm (QLQ-BN20) were used to compare HRQoL between patients assigned to concurrent chemoradiotherapy with temozolomide followed by 6 cycles of adjuvant temozolomide (arm A) and radiotherapy (RT) alone (arm B).
Results:Of the 90 patients in the study, 84 patients (93.3%) completed the baseline HRQoL questionnaire. Emotional functioning, fatigue, nausea and vomiting, dyspnea, constipation, appetite loss, diarrhea, seizures, itchy skin, drowsiness, hair loss, and bladder control were not affected by the addition of temozolomide. All other items did not differ significantly between arm A and arm B throughout treatment. Global health status particularly stayed consistent at the end of adjuvant temozolomide (p=0.47) and at the end of RT (p=0.33).
Conclusion:The addition of concurrent and adjuvant temozolomide did not show negative influence on HRQoL with improvement of progression-free survival for patients with anaplastic gliomas. The absence of systematic and clinically relevant changes in HRQoL suggests that an overall long-term net clinical benefit exists for concurrent and adjuvant temozolomide.
